Senate Wants Priority Review For 'Deemed' Biologics Not Approved By Deadline

 
• By Derrick Gingery
  
FDA entrance sign 2016
The 2020 transition for insulin and other products from drug to biologics regulation still worries legislators and others. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legislation

More from Pink Sheet